Elon Musk has given the next-generation Tesla Roadster a clear label, the best of the last of the human-driven cars” in a recent discussion.
Get the latest international news and world events from around the world.
AI-generated sensors open new paths for early cancer detection
Detecting cancer in the earliest stages could dramatically reduce cancer deaths because cancers are usually easier to treat when caught early. To help achieve that goal, MIT and Microsoft researchers are using artificial intelligence to design molecular sensors for early detection.
The researchers developed an AI model to design peptides (short proteins) that are targeted by enzymes called proteases, which are overactive in cancer cells. Nanoparticles coated with these peptides can act as sensors that give off a signal if cancer-linked proteases are present anywhere in the body.
Depending on which proteases are detected, doctors would be able to diagnose the particular type of cancer that is present. These signals could be detected using a simple urine test that could even be done at home.
Single-cell and spatial profiling highlights TB-induced myofibroblasts as drivers of lung pathology
In a new study from Ian M. Mbano, Nuo Liu, Paul T. Elkington, Alex K. Shalek, Alasdair Leslie (University of KwaZulu-Natal) and colleagues, single-cell and spatial transcriptomics of human TB lung tissues from individuals in South Africa revealed that MMP1⁺CXCL5⁺ fibroblasts & SPP1⁺ macrophages are linked to TB disease & TB lung granuloma.
Ian M. Mbano, Nuo Liu, Marc H. Wadsworth, Mark J. Chambers, Thabo Mpotje, Osaretin E. Asowata, Sarah K. Nyquist, Kievershen Nargan, Duran Ramsuran, Farina Karim, Travis K. Hughes, Joshua D. Bromley, Robert Krause, Threnesan Naidoo, Liku B. Tezera, Michaela T. Reichmann, Sharie Keanne Ganchua, Henrik N. Kløverpris, Kaylesh J. Dullabh, Rajhmun Madansein, Sergio Triana, Adrie J.C. Steyn, Bonnie Berger, Mohlopheni J. Marakalala, Sarah M. Fortune, JoAnne L. Flynn, Paul T. Elkington, Alex K. Shalek, Alasdair Leslie; Single-cell and spatial profiling highlights TB-induced myofibroblasts as drivers of lung pathology. J Exp Med 2 March 2026; 223 : e20251067. doi: https://doi.org/10.1084/jem.20251067
Download citation file:
When the “Eye Falls”Diagnosing Orbital Varix
Letters to the Editor.
The Letters section represents an opportunity for ongoing author debate and post-publication peer review. View our submission guidelines for Letters to the Editor before submitting your comment.
How energy, immune and vascular changes linked to ME/CFS
The study compared whole blood samples from 61 people meeting clinical diagnostic criteria for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) with samples from healthy age-and sex-matched volunteers.
White blood cells from ME/CFS patients showed evidence of ‘energy stress’ in the form of higher levels of adenosine monophosphate (AMP) and adenosine diphosphate (ADP), indicating reduced generation of adenosine triphosphate (ATP), the key energy source within cells.
Profiling of immune cell populations revealed a trend toward less mature subsets of T-lymphocyte subsets, dendritic cells and natural killer cells in people with ME/CSF.
Comprehensive analysis of plasma proteins highlighted disruptions of vascular and immune homeostasis in patients with ME/CFS. Levels of proteins associated with activation of the endothelium – the innermost lining of blood vessels – and remodelling of vessel walls were higher, while levels of circulating immunoglobulin-related proteins were lower.
Although cellular energy dysfunction and altered immune profiles have been noted before in patients with ME/CFS, previous studies have often focused on a single analytical platform without looking at concurrence and interactions.
“ME/CFS is a complex disorder with undefined mechanisms, limited diagnostic tools and treatments,” said the senior author of the study. “Our findings provide further insights into the clinical and biological complexity of ME/CFS.”
Harnessing Wearable Tech in Gastrointestinal Care
Wearable technologies have the potential to transform gastrointestinal care by enabling continuous monitoring of activity in patients with cirrhosis and aiding in the early detection of hepatic encephalopathy. While these innovations provide valuable clinical insights, further efforts are needed to address challenges related to implementation and data management.
Current research into wearable technology in liver disease supports these possibilities. Studies of wrist-worn activity monitors have shown that reduced activity is associated with increased waitlist mortality among liver transplant candidates, as well as increased hospital admissions and mortality in patients with cirrhosis. Other investigations with wearables have linked sleep disturbances to poorer post-liver transplant outcomes and explored skin patches and transdermal sensors for detecting blood alcohol levels and inflammatory markers predictive of outcomes in cirrhosis, Buckholz said.
A major barrier to widespread implementation in clinical practices is the so-called “wearable paradox,” whereby early adopters of wearable technology tend to be relatively healthy, whereas those at highest risk are less likely to already use such devices, Buckholz noted. Increasing access, understanding, and uptake in vulnerable populations will therefore be critical.
Additional challenges include determining how to distill massive volumes of wearable data into concise formats that can be incorporated into electronic medical records (EMRs) and easily communicated to patients.
Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: An Open-Label, Multicenter Randomized Clinical Trial
RCT: In patients with Chagas-related HFrEF, sacubitril/valsartan did not reduce rates of cardiovascular death or heart failure hospitalization compared with enalapril.
Although there was a greater reduction in NT-proBNP with sacubitril/valsartan, this did not impact observed clinical outcomes. These findings, in line with the BENEFIT trial, highlight the limited effect of biomarker improvements and antiparasitic therapy on clinical endpoints for Chagas disease.
The most common and severe complication of Chagas disease in its chronic phase is cardiomyopathy, which occurs in 30% to 40% of persons who are infected and can present as chronic myocarditis, conduction system abnormalities, cardioembolic episodes, heart failure (HF), and sudden death.5,11,12 Chagas cardiomyopathy is distinguished by its unique clinical features, including focal myocardial fibrosis, arrhythmogenicity, and ventricular aneurysm formation as well as a markedly high mortality rate, even in the absence of typical comorbidities.13 The reasons patients with HF due to Chagas disease have such a poor prognosis are not fully understood but may include persistent immune-mediated myocardial inflammation triggered by chronic parasitic infection, hypercoagulable state, right ventricular dysfunction, microvascular dysfunction, autonomic disturbance, high rates of ventricular arrhythmias, elevated risk of stroke, conduction disturbances, and ventricular aneurysm formation.5,13,14
Whether guideline-recommended medical therapies for HF are effective in patients with Chagas cardiomyopathy is unknown. No randomized clinical trial to date has been powered to test the efficacy and safety of any treatment in patients with HF caused by Chagas disease, and these patients were not adequately represented in pivotal HF trials.14 Although large randomized clinical trials are lacking, enalapril was selected as the comparator as a standard of care for HF management, including in patients with Chagas cardiomyopathy. The study by Szajnbok et al demonstrated that enalapril improved functional class and reduced heart size in patients with chronic Chagas heart disease, suggesting a beneficial hemodynamic effect.15 More recently, Penitente et al reported that enalapril reduced myocardial fibrosis and improved cardiac function in a murine model of chronic Chagas disease, supporting its role in modulating disease progression.16 Sacubitril/valsartan may offer incremental benefit over enalapril in patients with Chagas disease not only through neurohormonal and vasodilator effects but also by mitigating myocardial fibrosis and arrhythmias.14 Additionally, fully understanding the safety of HF treatments in this population is important, as these patients have more dysfunction of the right ventricle and lower blood pressure compared with other HF etiologies.14
Therefore, the PARACHUTE-HF (Prevention and Reduction of Adverse Outcomes in Chagasic Heart Failure Trial Evaluation) trial was designed to prospectively evaluate the efficacy and safety of the angiotensin receptor-neprilysin inhibitor sacubitril/valsartan in patients with HF with reduced ejection fraction (HFrEF) caused by Chagas disease.
Hominin fossils from Morocco may be close ancestors of modern humans
The jawbones and vertebrae of a hominin that lived 773,000 years ago have been found in North Africa and could represent a common ancestor of Homo sapiens, Neanderthals and Denisovans.